Transgenic expression of secreted/active IL-33 results in type 2 immune responses and eosinophilic esophagitis
Alfred D. Doyle(Mayo Clinic in Arizona), Hirohito Kita(Mayo Clinic), Rish K. Pai(Cincinnati Children's Hospital Medical Center), Matthew A. Rank(Mayo Clinic in Arizona), Koji Iijima(WinnMed), Mia Y. Masuda(Mayo Clinic in Arizona), Huijun Luo(Johnson University), Takao Kobayashi(Japanese Society of Medical Oncology)
Cited by 5
Related Papers
Anaphylaxis—a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis
|Journal of Allergy and Clinical Immunology|2020|676
IL-33–Responsive Lineage−CD25+CD44hi Lymphoid Cells Mediate Innate Type 2 Immunity and Allergic Inflammation in the Lungs
|The Journal of Immunology|2011|537
Drug allergy: A 2022 practice parameter update
|Journal of Allergy and Clinical Immunology|2022|504
Rhinitis 2020: A practice parameter update
|Journal of Allergy and Clinical Immunology|2020|399
Enhanced innate type 2 immune response in peripheral blood from patients with asthma
|Journal of Allergy and Clinical Immunology|2014|379